QuidelOrtho Corp QDEL
Our vision is to advance diagnostics to power a healthier future. 10-K, Item 1
- Employees
- 6,500
- Headquarters
- San Diego, CA
- CEO
- Brian J. Blaser
- Next results
- around Feb 10, 2027
QDEL among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
10 new risk paragraphs and 3 accounting facts worth reading about. 10-K filed Feb 19, 2026 against Feb 27, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
3facts worth reading about the other 8 checks found nothing to note
-
Receivables growing faster than revenueReceivables +47.7% ($282.4M to $417.0M) vs revenue -1.9% ($2.8B to $2.7B), +49.6 pts apart
-
Inventory growing faster than revenueInventory +8.2% ($533.7M to $577.6M) vs revenue -1.9% ($2.8B to $2.7B), +10.1 pts apart
-
Auditor change8-K item 4.01 (change in certifying accountant) filed Mar 4, 2025
-
Cash from operations $105.2M vs net income −$1.1B (FY ending Dec 28, 2025)
7 more checks with nothing to note
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Allowance for contractual rebates; Goodwill impairment assessment
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
10 paragraphs in Risk Factors that were not in the 10-K filed Feb 27, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
Our collaboration arrangements may not operate according to our business strategy and if we are unable to maintain our collaboration arrangements, or if these collaboration arrangements are not successful, our results of operations could be materially adversely affected.
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
We may engage in strategic transactions, including acquisitions, investments, joint ventures, licensing arrangements and other strategic relationships, undertake strategic restructurings or divest, spin-off or discontinue certain business operations, and may not successfully identify or consummate these strategic transactions;…
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
We may also undertake initiatives to restructure or streamline our operations in order to achieve cost savings and improve operational efficiency. For example, in the second quarter of 2025, we launched the Optimization Plan that aims to (i) realign our costs with our long-term revenue expectations, (ii) drive operational efficiencies…
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
Outside the U.S., commercialization is subject to diverse and evolving regulatory regimes, including, for example, the EU IVDR, Health Canada licensing and the NMPA in China. These regulatory regimes may require local clinical evidence, language- and country-specific labeling, post-market surveillance and vigilance reporting, and…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $3.3B | $3.0B | $2.8B | $2.7B |
| Net income | $548.7M | −$10.1M | −$2.1B | −$1.1B |
| Operating cash flow | $885.3M | $280.2M | $83.0M | $105.2M |
| Free cash flow | $744.4M | $70.9M | −$112.1M | −$83.0M |
Revenue, FY2020 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$2.7B ▼ 1.9% in FY2025−$1.1B in FY2025−$83.0M in FY2025
Recent filings
2 filings in the last 30 days · SEC EDGAR
-
10-QNov 4, 2026Quarterly report (10-Q) period ended Sep 27, 2026
-
8-KNov 3, 2026Quarterly results, Director or officer change 8-K items 2.02, 5.02
About the company
QuidelOrtho Corp, San Diego, CA · from the 10-K filed Feb 19, 2026
Our vision is to advance diagnostics to power a healthier future. With our expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, we aim to support clarity for clinicians and patients to help create better health outcomes. Our global infrastructure and commercial reach support our customers across more than 140 countries and territories with quality diagnostics, a broad test portfolio and market-leading service. We operate globally with manufacturing facilities in the U.S., U.K. and China and with sales centers, administrative offices and warehouses located throughout the world.
- Headquarters
- San Diego, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- January 1
- Last results
- Nov 3, 2026
Employees, at the top of the page: "As of December 28, 2025, we had approximately 6,500 employees worldwide, with approximately 3,600 employees in the U" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
The 10-K filed Feb 19, 2026 (open at SEC), compared with the 10-K filed Feb 27, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/QDEL/export.csv") into a cell.